+91-98 455 710 46 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
18 Aug 2015

R-PHARM US Acquires IXEMPRA(R) (ixabepilone) From Bristol-Myers Squibb and Launches U.S. Commercial Operations

R-PHARM US announces the acquisition of IXEMPRA (ixabepilone) from Bristol-Myers Squibb (BMY). IXEMPRA received marketing approval from the U.S. Food and Drug Administration in 2007 and in 18 other markets globally. IXEMPRA is indicated as monotherapy or in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine. With the acquisition, R-PHARM US has launched its U.S. commercial operations, and it is now responsible for all activities surrounding IXEMPRA’s manufacture, distribution, sales, and reimbursement.

On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. In November 2008, the EMEA has refused a marketing authorisation for Ixabepilone.

 

Leave a Reply


The reCAPTCHA verification period has expired. Please reload the page.

Upskill Your Pharma Knowledge

Explore Next Gen Learning

Case Studies & Caselets | Simulation Based Learning | E-Lectures | Online Self Competency Assessments

Thank You for Subscription!